A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

NCT07299084 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing how different fasting times and stopping the diabetes medication tirzepatide affect stomach contents after eating in adults with type 2 diabetes or overweight/obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 40 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-01 · est. completion 2026-11

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT07299084 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2, Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07299084 ↗